This company listing is no longer active
DSM2 Stock Overview
Provides solutions for nutrition, health, and beauty businesses in the Switzerland, Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
DSM-Firmenich AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$113.95 |
| 52 Week High | US$157.30 |
| 52 Week Low | US$106.00 |
| Beta | 0.72 |
| 1 Month Change | -3.14% |
| 3 Month Change | -3.06% |
| 1 Year Change | -28.11% |
| 3 Year Change | -3.76% |
| 5 Year Change | 28.73% |
| Change since IPO | 105.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| DSM2 | Chemicals | Market | |
|---|---|---|---|
| 7D | 0.3% | 0% | 0% |
| 1Y | -28.1% | 0% | 0% |
Return vs Industry: DSM2 underperformed the German Chemicals industry which returned -12.6% over the past year.
Return vs Market: DSM2 underperformed the German Market which returned -8.2% over the past year.
Price Volatility
| DSM2 volatility | |
|---|---|
| DSM2 Average Weekly Movement | 3.4% |
| Chemicals Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in DE Market | 0% |
| 10% least volatile stocks in DE Market | 0% |
Stable Share Price: DSM2 has not had significant price volatility in the past 3 months.
Volatility Over Time: DSM2's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1902 | 19,973 | Dimitri de Vreeze | www.dsm-firmenich.com |
DSM-Firmenich AG, a science-based company, engages in health and nutrition businesses in the Netherlands, Switzerland, rest of Europe, North America, Latin America, China, rest of Asia, and internationally. It operates through Animal Nutrition & Health (ANH); Health, Nutrition & Care (HNC); and Food & Beverage segments. The Animal Nutrition & Health segment offers essential products, including vitamins, premixes, and carotenoids; performance solutions, such as enzymes, microbes, and eubiotics; precision services comprising support with data analysis to measure animal health and environmental footprint on farm level and feed safety; and methane reducing feed additive for ruminants.
DSM-Firmenich AG Fundamentals Summary
| DSM2 fundamental statistics | |
|---|---|
| Market cap | n/a |
| Earnings (TTM) | US$454.00m |
| Revenue (TTM) | US$8.39b |
1.7x
P/E Ratio0.1x
P/S RatioIs DSM2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DSM2 income statement (TTM) | |
|---|---|
| Revenue | US$8.39b |
| Cost of Revenue | US$5.70b |
| Gross Profit | US$2.69b |
| Other Expenses | US$2.24b |
| Earnings | US$454.00m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
Aug 02, 2023
| Earnings per share (EPS) | 67.80 |
| Gross Margin | 32.06% |
| Net Profit Margin | 5.41% |
| Debt/Equity Ratio | 26.6% |
How did DSM2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | |
| End of Day Share Price | |
| Earnings | |
| Annual Earnings |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
DSM-Firmenich AG is covered by 61 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mutlu Gundogan | ABN AMRO Bank N.V. |
| Martin Schnee | AlphaValue |
| Volker Bosse | Baader Helvea Equity Research |